Brainstorm Cell Therapeutics Reports $15K Cash, $2.1M Loss, Phase 3b ALS Trial Contingent on Funding

summarizeSummary

Brainstorm Cell Therapeutics reported critically low cash reserves of $15,000 and a $2.1 million quarterly net loss, confirming severe financial distress, while simultaneously announcing preparations for a Phase 3b ALS trial contingent on securing necessary financing.

check_boxKey Events

• Critically Low Cash Reserves

  The company reported cash and cash equivalents of only $15,000 as of March 31, 2026, down from $29,000 at year-end 2025, indicating an immediate and severe liquidity crisis.

• Significant Quarterly Net Loss

  Brainstorm Cell Therapeutics posted a net loss of $2.1 million for the first quarter of 2026, with operating expenses of $2.0 million, highlighting an unsustainable burn rate relative to its cash position.

• Phase 3b ALS Trial Preparations Underway

  The company is continuing preparations for its Phase 3b ENDURANCE study for NurOwn in ALS, with Part A completion expected to support a new Biologics License Application (BLA) submission.

• Clinical Trial Contingent on Funding

  The initiation of the planned Phase 3b ENDURANCE study is explicitly stated as "subject to securing the necessary financing," underscoring the critical funding gap for its core development program.

auto_awesomeAnalysis

This filing confirms Brainstorm Cell Therapeutics' dire financial state with a cash balance of only $15,000 and a quarterly burn rate of over $2 million, reinforcing the going concern warnings from recent filings. While the company is advancing its NurOwn ALS therapy to a Phase 3b trial, the explicit contingency on "securing the necessary financing" casts significant doubt on its ability to execute, given its current cash position and substantial liabilities. This situation presents an existential challenge for the company.